Not yet recruiting NCT07700472
Endoscopic Ultrasound-Guided Ethanol Ablation for Aldosterone-Producing Adenoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Endoscopic Ultrasound-Guided Ethanol Ablation.
- Who it may be relevant to
- Registry conditions: Primary Aldosteronism, Aldosterone-Producing Adenoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Endoscopic Ultrasound-Guided Ethanol Ablation of Aldosterone-Producing Adenomas
Overview
This is a prospective, single-center, single-arm study evaluating endoscopic ultrasound-guided ethanol ablation for left-sided aldosterone-producing adenoma. Eligible participants will receive the ablation procedure and be followed for safety, imaging response, biochemical remission, and clinical remission. The study is expected to enroll 30 participants.
Interventions
- Procedure Endoscopic Ultrasound-Guided Ethanol Ablation
Participants with left-sided aldosterone-producing adenoma undergo endoscopic ultrasound-guided ethanol ablation under real-time endoscopic ultrasound guidance.
Primary outcome measures
- Procedure-related major adverse events [Time frame: Within 24-48 hours after endoscopic ultrasound-guided ethanol ablation]
Secondary outcome measures (3)
- Complete tumor ablation on imaging [Time frame: 6 months after endoscopic ultrasound-guided ethanol ablation]
- Complete biochemical remission rate [Time frame: 6 months after endoscopic ultrasound-guided ethanol ablation]
- Complete clinical remission rate [Time frame: 6 months after endoscopic ultrasound-guided ethanol ablation]
Eligibility criteria
Inclusion criteria
- Diagnosis of left-sided aldosterone-producing adrenal adenoma.
- Unwillingness to undergo adrenalectomy or presence of contraindications to surgery.
- Ability and willingness to provide written informed consent.
Exclusion criteria
- History of alcohol allergy.
- Inability to discontinue beta-blockers.
- Inability to discontinue anticoagulants, antiplatelet agents, or glucocorticoids.
- Platelet count <50 × 10\^9/L or uncorrectable coagulation dysfunction.
- Imaging findings suggestive of adrenal cyst, adrenal hematoma, or myelolipoma.
- Presence of other active malignancies.
- Pregnancy or breastfeeding; alcohol abuse; drug abuse; or mental disorder that may interfere with study participation.
- Severe comorbid conditions, including any of the following: New York Heart Association (NYHA) class III-IV heart failure or hospitalization for worsening chronic heart failure within the previous 3 months; stroke or acute coronary syndrome within the previous 3 months; severe anemia (hemoglobin <60 g/L); severe hepatic disease (alanine aminotransferase ≥3 × the upper limit of normal); severe renal disease requiring dialysis or estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m²; systemic inflammatory response syndrome (SIRS); poorly controlled diabetes mellitus (fasting blood glucose ≥13.3 mmol/L); severe obesity (body mass index ≥35 kg/m²); untreated aneurysm; or any other severe medical condition that may interfere with treatment or study follow-up.
- Poor compliance or any other condition that, in the investigator's judgment, would make the participant unsuitable for the study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- The First Affiliated Hospital of Chongqing Medical University — Chongqing
Publications
- Deng L, Hao Y, Zhang X, Li Q, Hu J, Yang S. Endoscopic ultrasound-guided ethanol ablation for aldosterone-producing adenoma. Endoscopy. 2026 Jun;58(S 02):E702-E703. doi: 10.1055/a-2875-0099. Epub 2026 Jun 11. No abstract available. PMID 42276127
Identifiers
NCT: NCT07700472 · 2026-0558-01